Authors’ Disclosures
Durecki, P.
EMD
Y. Shyr reports grants from NIH/NCI during the conduct of the study; grants from NIH outside the submitted work. S. Boerner reports grants from NCI-CTEP and Rising Tide Foundation during the conduct of the study. D. Durecki reports grants from NIH/NCI UM1CA186689 during the conduct of the study. J. Drappatz reports other from Pfizer, GSK, Gilead, and Vertex outside the submitted work. V. Puduvalli reports personal fees and other from Servier and Novocure, other from Karyopharm, and personal fees from Orbus therapeutics during the conduct of the study; other from Amarin and Gilead outside the submitted work. F.S. Lieberman reports grants from ABTC during the conduct of the study; grants from Novocure, Chimerix, Blue Diamond Therapeutics, and Abbvie outside the submitted work. J. Gonzalez reports other from AstraZeneca outside the submitted work. P. Giglio reports grants from NCI during the conduct of the study; other from Vanguard Funds; grants from BioMimetix, Denovo Biopharma, Institut de Recherches Internationales Servier, Novocure, and Prelude Therapeutics outside the submitted work. R.S. Bindra reports a patent to 62/344,678 pending. A. Omuro reports grants from Arcus Biosciences; personal fees from Pyramid, Merck, Kiyatec, and Ono outside the submitted work. P. LoRusso reports other from AbbVie, Agios, Five Prime, GenMab, Halozyme, Roche-Genetech, Genentech, CytomX, Takeda, Sotio, Cybrexa, Agenus, Tyme, IQVIA, TRIGR, Pfizer, ImmunoMet, Black Diamond, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics, Kyowa Kirin Pharmaceutical, Kineta, Zentalis, Molecular Templates, ABL Bio, SK Life Science, STCube Pharmaceuticals, Bayer, I-Mab, Seagen, imCheck, Relay Therapeutics, Stemline, Compass BADX, Mekanist, Mersana Therapeutics, BAKX Therapeutics, Scenic Biotech, Qualigen, Roivant, and NeuroTrials outside the submitted work. No disclosures were reported by the other authors.